Table 3 Sensitivity and specificity (with confidence intervals) observed in Reimann et al. [1] and prior studies of myPath melanoma (using clinically-validated classification system)
From: Reply to Reimann et al.
Study | Reference standard | Sensitivity | 95% Confidence interval | Specificity | 95% Confidence interval |
|---|---|---|---|---|---|
Clarke et al. [14] | Histopathology | 94% | 90%, 97% | 90% | 85, 93% |
Clarke et al. [10] | Histopathology | 92% | 86%, 95% | 93% | 90%, 95% |
Reimann et al. [1] | Histopathology | ||||
'Unequivocal' | 83% | 71%, 91% | 89% | 81%, 94% | |
'Ambiguous' | 67% | 38%, 88% | 96% | 80%, 100% | |
Ko et al. [11] | Clinical outcome | 94% | 87%, 98% | 96% | 89%, 99% |
